Exploiting viral natural history for vaccine development

Medical Microbiology and Immunology
Peter A Barry

Abstract

The partial successes of the Phase 2 gB-based vaccine trials for HCMV highlight the very real likelihood that vaccine-mediated induction of antibodies that neutralize the fusion pathway of fibroblast infection is not sufficient as a singular strategy to confer protective efficacy against primary HCMV infection. Alternative strategies that serve as adjuncts to gB-based vaccines are likely required to target different aspects of the complex lifecycle of HCMV infection. There has been considerable recent interest in targeting the gH/gL/UL128/UL130/UL131 pentamer complex (gH/gL-PC) to neutralize the endocytic pathway of HCMV infection of epithelial and endothelial cells. Since both cell types are critical during primary mucosal infection, intrahost spread, and shedding of HCMV in an infected host, the gH/gL-PC represents a high-value target for vaccination to interrupt the HCMV lifecycle. The natural history of HCMV is exceedingly complex and incompletely resolved, and the protective efficacy generated by gH/gL-PC remains to be validated in clinical trials. Yet, there are salient aspects of its lifecycle that offer clues about how other novel vaccine strategies can be targeted to especially susceptible parts of the viral proteome t...Continue Reading

References

May 1, 1971·The Journal of Infectious Diseases·J B Hanshaw
Mar 31, 1995·Journal of Molecular Biology·D J McGeochE A Telford
Dec 1, 1996·The Journal of General Virology·M MendelsonJ Sinclair
Jan 1, 1996·Intervirology·W J Britt, M Mach
Mar 8, 2000·Virology·K M LockridgeP A Barry
May 3, 2001·The New England Journal of Medicine·S B BoppanaW J Britt
Jan 5, 2002·Journal of Virology·Juliet V SpencerThomas J Schall
Jul 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·Brandi C JonesMark R Walter
Oct 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dong YuThomas Shenk
Nov 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Walter DunnFenyong Liu
Dec 23, 2004·Journal of Virology·Duncan J McGeoch, Derek Gatherer
Apr 14, 2005·Journal of Virology·Nupur T PandeKlaus Früh
Sep 9, 2005·The Journal of Experimental Medicine·Andrew W SylwesterLouis J Picker
May 9, 2007·The Journal of Experimental Medicine·Ian R HumphreysCarl F Ware
Jan 29, 2008·Virology·Juliet V SpencerBarry Slobedman
Jul 31, 2009·Journal of Virology·Barry SlobedmanAllison Abendroth
Jan 20, 2010·Reviews in Medical Virology·M Grazia Revello, Giuseppe Gerna
Feb 16, 2010·Nature Reviews. Immunology·Margarida Saraiva, Anne O'Garra
Dec 15, 2010·Proceedings of the National Academy of Sciences of the United States of America·W L William Chang, Peter A Barry
Feb 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chengbin WangMichael J Cannon
Mar 9, 2012·Advances in Experimental Medicine and Biology·Pablo Engel, Ana Angulo
May 25, 2013·Science·Scott G HansenLouis J Picker
Aug 16, 2013·Journal of Virology·Meghan K EberhardtPeter A Barry
Apr 1, 2014·Viruses·Jesse D Deere, Peter A Barry

❮ Previous
Next ❯

Citations

Nov 4, 2016·Medical Microbiology and Immunology·Bodo Plachter
Jul 25, 2017·Medical Microbiology and Immunology·Vera SeidelKatharina Weizsäcker
Jun 28, 2019·Frontiers in Immunology·A Raj Kumar Patro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antibody Repertoire Diversity

Antibody repertoire diversity and its role during natural infection is a prerequisite for molecular and structural elucidation of functionally protective immunity. Discover the latest insights into antibody diversity here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis